LeBlanc, Richard http://orcid.org/0000-0001-9990-2183
Ahmad, Imran http://orcid.org/0000-0003-1899-0164
Terra, Rafik
Boudreault, Jean-Samuel
Ogez, David http://orcid.org/0000-0002-7441-9678
Lamore, Kristopher http://orcid.org/0000-0002-8878-2662
Delisle, Jean-Sébastien
Bambace, Nadia
Bernard, Léa
Cohen, Sandra
Kiss, Thomas
Lachance, Silvy http://orcid.org/0000-0001-7882-9335
Landais, Séverine
Lemieux-Blanchard, Émilie
Sauvageau, Guy http://orcid.org/0000-0002-4333-7266
Sebag, Michael
Roy, Denis Claude
Roy, Jean
Funding for this research was provided by:
Myeloma Canada Chair of Université de Montréal
Maryse and William Brock Chair in Applied Research into Stem Cell Transplantation (Holder J. Roy
Article History
Received: 29 August 2021
Revised: 29 October 2021
Accepted: 15 November 2021
First Online: 29 November 2021
Competing interests
: RL: consultancy for Bristol Myers Squibb/Celgene, Janssen, Amgen, Sanofi and Takeda; research funding as a co-investigator from BMS/Celgene. IA: consultancy for Novartis; research funding from Sanofi Genzyme. JSBP: consultancy for Bristol Myers Squibb/Celgene, Janssen and Amgen. SC: consultancy for ExCellThera Inc; potential royalties from ExCellThera Inc. SLac: consultancy for Novartis and Jazz Pharmaceuticals Canada; potential royalties from ExCellThera Inc. ÉLB: consultancy for Bristol Myers Squibb/Celgene and Janssen. GS: employment: CEO - ExCellThera Inc, consultancy for Bristol Myers Squibb, ownership interest in a start-up company for ExCellThera, research funding from ExCellThera Inc, Royalties from ExCellThera Inc. MS: consultancy for Bristol Myers Squibb/Celgene, Janssen, Amgen, Takeda. DCR: consultancy for Kiadis Pharma. JR: consultancy for Bristol Myers Squibb/Celgene, Janssen, Amgen, Sanofi and Takeda; research funding as a principal investigator from BMS/Celgene; potential royalties from ExCellThera Inc. RT, DO, KL, JSD, NB, LB, TK, SLan: no conflict of interests.